Mycophenolate mofetil may be an alternative for maintenance therapy of Behçet syndrome uveitis: a single-center retrospective analysis
Rheumatology International · 2023
DOI: 10.1007/s00296-023-05420-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Rheumatology International, 2023. Verfasst von Didar Ucar und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Cerrahpaşa Medical Faculty Istanbul University-Cerrahpaşa, Istanbul, Turkey. Hauptthemen laut MEDLINE: Behcet Syndrome, Uveitis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
Experience with mycophenolate in uveitis due to Behçet syndrome (BS) is limited. Twelve patients with panuveitis or posterior uveitis who were started mycophenolate were included. Data on demographic characteristics, therapies, ocular attacks, and adverse events were extracted from patient charts. Seven patients with BS uveitis were prescribed mycophenolate for remission induction, of which 6 were refractory/intolerant to conventional immunosuppressives. Mycophenolate was combined with anti-TNFs in 3 patients, resulting in no further ocular attacks. Mycophenolate had to be stopped in the fourth patient due to adverse events. The remaining 3 patients continued to have ocular attacks and were switched to other agents without any drop in visual acuity. Among the 5 patients who were prescribed mycophenolate for maintenance, 2 were relapse free, but 3 experienced ocular attacks. One patient had an exacerbation of mucocutaneous lesions, and 2 experienced adverse events. Mycophenolate monotherapy may not be adequate for remission induction of refractory BS uveitis, but it can be a safe and effective alternative when combined with a biologic agent. It may also be an option for maintenance therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Cerrahpaşa Medical Faculty Istanbul University-Cerrahpaşa, Istanbul, Turkey.
- Behçet's Disease Research Center, Istanbul University-Cerrahpaşa, Istanbul, Turkey.
- Behçet's Disease Research Center, Istanbul University-Cerrahpaşa, Istanbul, Turkey. nihalesatoglu@gmail.com.
- Division of Rheumatology, Department of Internal Medicine, Cerrahpaşa Medical Faculty Istanbul University-Cerrahpaşa, Istanbul, Turkey. nihalesatoglu@gmail.com.
- Division of Rheumatology, Department of Internal Medicine, Cerrahpaşa Medical Faculty Istanbul University-Cerrahpaşa, Istanbul, Turkey.
Zitieren
APA
Ucar, D., Esatoglu, S. N., Cerme, E., Batu-Oto, B., Hamuryudan, V., Seyahi, E., Melikoglu, M., Fresko, I., Ozyazgan, Y., & Hatemi, G. (2023). Mycophenolate mofetil may be an alternative for maintenance therapy of Behçet syndrome uveitis: a single-center retrospective analysis. Rheumatology International. https://doi.org/10.1007/s00296-023-05420-4
Vancouver
Ucar D, Esatoglu SN, Cerme E, Batu-Oto B, Hamuryudan V, Seyahi E, et al. Mycophenolate mofetil may be an alternative for maintenance therapy of Behçet syndrome uveitis: a single-center retrospective analysis. Rheumatology International. 2023. doi:10.1007/s00296-023-05420-4
BibTeX
@article{Ucar2023,
author = {Ucar, Didar and Esatoglu, Sinem Nihal and Cerme, Emir and Batu-Oto, Bilge and Hamuryudan, Vedat and Seyahi, Emire and Melikoglu, Melike and Fresko, Izzet and Ozyazgan, Yılmaz and Hatemi, Gulen},
title = {Mycophenolate mofetil may be an alternative for maintenance therapy of Behçet syndrome uveitis: a single-center retrospective analysis},
journal = {Rheumatology International},
year = {2023},
doi = {10.1007/s00296-023-05420-4}
}
EUVIMED